A Study Comparing AIN457 to Placebo in Subjects With a Diagnosis of Moderate to Severe Stable Plaque Psoriasis

NCT ID: NCT00669916

Last Updated: 2015-04-10

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 36 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2007-02-28
• Study Completion Date: 2007-11-30

Brief Summary

This is a two-arm, parallel group, double-blind, placebo-controlled proof-of-concept study comparing 3 mg/kg of AIN457 to placebo. Subjects with a diagnosis of moderate to severe stable plaque psoriasis will be randomized to receive either AIN457 or placebo. AIN457 or placebo will be administered by single infusion at baseline and subjects will be observed for up to 26 weeks following the infusion.

Conditions

Plaque Psoriasis

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: BASIC_SCIENCE
• Blinding Strategy: DOUBLE

Study Groups

AIN457

AIN457A 3mg/kg was administered intravenously as a single dose.

Group Type: EXPERIMENTAL

AIN457

Intervention Type: BIOLOGICAL

single infusion of 3 mg/kg

Placebo

Placebo was administered intravenously as a single dose.

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

single infusion of placebo

Interventions

AIN457

single infusion of 3 mg/kg

Intervention Type: BIOLOGICAL

Placebo

single infusion of placebo

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Males or females, aged 18-69 at time of consent.
• Post menopausal or surgically sterile female patients are allowed. Male patients must be willing to use contraception method at least for 3 months following the completion of the study. Women of child-bearing potential will not be allowed to participate.
• Diagnosis of plaque psoriasis for at least 6 months prior to screening. The patients must meet both of the following criterion:

1. Coverage of the body surface area (BSA) of 10% or more with plaques

2. A score of 3 or more on the IGA scale

• Stable plaque psoriasis at screening and randomization.
• PASI score of 12 or greater at randomization.
• Able to communicate well with the investigator, and to understand and comply with the requirements of the study. Understand and sign the written informed consent.
• Patients must have normal laboratory values for screening laboratory test results of hematological (hemoglobin, WBCs, neutrophils, platelets) and renal (serum creatinine) assessments. For the transaminases, aspartate aminotransferase and alanine aminotransferase, levels 1.5 times the upper limit of normal will be accepted. For the additional hepatic laboratory results (alkaline phosphatase, gamma-glutamyltransferase, bilirubin), patients must have non-clinically significant values.

Exclusion Criteria

• Currently have any of the nonplaque forms of psoriasis: erythrodermic, guttate, or pustular.
• Currently have drug-induced psoriasis (new onset or exacerbation of psoriasis from beta blockers, calcium channel blockers, or lithium).
• Men who are planning to initiate a pregnancy while enrolled in the study or for 3 months following completion of the study.
• Women of child-bearing potential are not allowed in the study.
• Used any investigational drug within the previous 4 weeks.
• Recent previous treatment with anti-TNF-α therapy (or other biological therapy), immunosuppressive agents such as cyclosporine, mycophenolate, pimecrolimus, or tacrolimus. The following washout period will be required for such patients to be eligible to participate in the trial.

1. 2 months washout prior to screening for etanercept, adalimumab, or infliximab.

2. 1 month washout prior to screening for cyclosporine, mycophenolate, tacrolimus, and any systemic immunosuppressants including, but not limited to, methotrexate, azathioprine, 6-thioguanine, mercaptopurine, and hydroxyurea

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Novartis Pharmaceuticals

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Novartis Pharmaceuticals

Role: STUDY_DIRECTOR

Novartis Pharmaceuticals

References

Hueber W, Patel DD, Dryja T, Wright AM, Koroleva I, Bruin G, Antoni C, Draelos Z, Gold MH; Psoriasis Study Group; Durez P, Tak PP, Gomez-Reino JJ; Rheumatoid Arthritis Study Group; Foster CS, Kim RY, Samson CM, Falk NS, Chu DS, Callanan D, Nguyen QD; Uveitis Study Group; Rose K, Haider A, Di Padova F. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med. 2010 Oct 6;2(52):52ra72. doi: 10.1126/scitranslmed.3001107.

Reference Type: DERIVED

PMID: 20926833 (View on PubMed)

Other Identifiers

CAIN457A2102

Identifier Type: -

Identifier Source: org_study_id